Oxford BioMedica plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oxford BioMedica plc
Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.
If the bill on the Biosimilar Red Tape Elimination Act is passed, all biosimilars would be deemed interchangeable on US FDA approval. Scrip takes a look at what empowering pharmacists could mean, what the generics substitution experience shows and where possible pain points lie
Plus deals from Huadong/Arcutis, SK Bioscience/Novavax, NeuroBio/MThera, CASI/Mundipharma/Acrotech, Amarin/Lotus and Synergy/Livzon.
System interoperability and building trust in AI capabilities are central to the strategic collaboration and organic growth plans at GE HealthCare, according to US and Canada regional president and CEO Catherine Estrampes, who spoke to In Vivo as the company released the findings of a major survey of clinicians and patients on future healthcare system needs.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Oxxon Therapeutics Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.